Precision BioSciences (DTIL) Projected to Announce Quarterly Earnings on Monday

Precision BioSciences (NASDAQ:DTIL) is anticipated to release its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect Precision BioSciences to announce earnings of ($0.85) per share and revenue of $1.38 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 9:30 AM ET.

Precision BioSciences (NASDAQ:DTIL) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.46). Precision BioSciences had a negative return on equity of 72.52% and a negative net margin of 96.73%. On average, analysts expect Precision BioSciences to post ($3.33) EPS for the current fiscal year and ($1.86) EPS for the next fiscal year.

Precision BioSciences Trading Down 5.1%

Shares of Precision BioSciences stock opened at $7.06 on Friday. Precision BioSciences has a 1 year low of $3.53 and a 1 year high of $9.62. The firm’s 50-day moving average is $6.90 and its 200 day moving average is $6.50. The company has a current ratio of 12.82, a quick ratio of 12.82 and a debt-to-equity ratio of 0.50.

Analyst Ratings Changes

Several brokerages have issued reports on DTIL. HC Wainwright reaffirmed a “buy” rating on shares of Precision BioSciences in a report on Monday, August 3rd. Wall Street Zen cut Precision BioSciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Precision BioSciences in a report on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $32.25.

About Precision BioSciences

Precision BioSciences, Inc is a biotechnology company developing gene-editing medicines using its proprietary ARCUS platform. ARCUS is based on engineered DNA-cutting enzymes designed to make targeted changes to genetic material, with the potential to remove, insert or correct DNA sequences in human cells.

The company’s research and development activities have focused primarily on in vivo gene editing, in which therapeutic editing components are delivered directly into the body. Its development programs have included potential treatments for conditions such as chronic hepatitis B infection, Duchenne muscular dystrophy and certain rare genetic disorders.